# A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)

> **NCT02634346** · PHASE3 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 403 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** ALK3831
- **DRUG:** Olanzapine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02634346
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2017-05-25
- **Final completion:** 2017-06-07
- **Target enrollment:** 403 (ACTUAL)
- **Last updated:** 2018-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02634346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02634346, "A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02634346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*